Understanding optimum ways to reduce pain and stress associated with medical procedures in paediatric populations reflects health-care providers' inherent mandate to do no harm. This is especially urgent in vulnerable preterm populations who undergo an average of 12 painful procedures daily while receiving neonatal care, 1 given our increasing understanding of the adverse effects of early pain exposure on later neurodevelopment and behaviour. 2 Several interventions-such as breastfeeding, 3 parent-infant skin-to-skin contact, 4 and sweet-tasting solutions 5 -have been shown to reduce biobehavioural pain response associated with needlerelated procedures. However, similar intervention efficacy to reduce the moderate-to-severe pain associated with commonly performed eye examinations to diagnose retinopathy of prematurity has not been reported. 6 Considering this gap in neonatal pain care, Caroline Hartley and colleagues report in The Lancet the findings of their single-centre, masked, randomised, placebo-controlled clinical trial, 7 in which they examined the analgesic effectiveness of 100 µg/kg of oral morphine sulfate compared with placebo in non-ventilated, stable, preterm neonates (born <32 weeks' gestation or with a birthweight of <1501 g) to reduce acute procedural pain after heel lance and consecutive retinopathy of prematurity eye examination. The trial is particularly novel in that the authors measured multimodal pain responses, including biobehavioural pain scores, noxiousevoked brain activity, and reflex withdrawal. Episodes of oxygen desaturation, bradycardia, tachycardia, apnoea, and requirement for increased respiratory support during the 6 h and 24 h after the procedure were also monitored.
Hartley and colleagues required a sample size of 132 neonates to detect a clinically meaningful reduction in the coprimary outcomes of Premature Infant Pain Profile-Revised (PIPP-R) score (2 point difference on the scale) after retinopathy of prematurity screening and 40% reduction in noxious-evoked brain activity after heel lancing. A final sample of 156 infants was proposed to allow for multiple births and 10% loss to followup. As per the a priori stopping boundary, the Data Monitoring Committee recommended that the trial be stopped after enrolment of 31 neonates. An appreciable increase was noted in the number of apnoea episodes, and a significant increase was seen in required respiratory support at 6 h and 24 h after morphine exposure. The authors reported no difference between groups in PIPP-R scores after retinopathy of prematurity eye examination (with morphine, mean 11·1 [SD 3·2]; with placebo, 10·5 [3·4]; mean difference 0·5, 95% CI -2·0 to 3·0; p=0·66). The magnitude of noxious-evoked brain activity after heel lancing also did not differ between groups (with morphine, 0·99 [IQR 0·40-1·56]; with placebo, 0·75 [0·33 to 1·22]; median difference 0·25, 95% CI -0·16 to 0·80; p=0·25).
This Article has several strengths. Most notably, the study aim addresses a highly relevant clinical concern, and the findings are consistent with previous work reporting that retinopathy of prematurity eye examinations are associated with moderate-to-severe pain responses in preterm neonates. 6 While not novel, safety concerns and recommendations for cautious administration and close monitoring are consistent with previous work using morphine for procedural pain treatment in nonventilated preterm neonates 8 and practice guidelines. 9 The study also has methodological limitations that should be noted. Although Hartley and colleagues acknowledge their study was significantly underpowered because of early cessation, they interpret a trend towards greater noxious-evoked brain activity in morphinetreated neonates, compared with those who received placebo, as a suggestion of no analgesic effect-a finding that is more likely attributable to type II error in view of the small sample size. In an underpowered trial, this trend and suggestion should not be interpreted as analgesic ineffectiveness. Despite these concerns, Hartley and colleagues are not the first to question the analgesic adequacy of morphine for procedural pain in preterm neonates, with previous work 10 reporting no difference in biobehavioural pain scores after heel lance in ventilated preterm neonates receiving a 100 µg/kg intravenous loading dose of morphine compared with placebo.
Several clinical considerations should also be noted when interpreting the results of this study. It is unusual in a clinical neonatal setting for painful procedures to be clustered so closely together, as was done in Hartley and colleagues' study, in view of previous findings 11 showing previous pain increased biobehavioural reactivity (physiological and facial pain responses, and body movements) in preterm infants during subsequent tactile procedures. Additionally, neonates who received placebo in this study received only swaddling during the heel lance as non-pharmacological pain management. However, recommendations for the ethical conduct of studies examining needle-related pain advise that all neonates should receive an optimum pain-relieving intervention, 12, 13 such as breastfeeding, 3 skin-to-skin contact, 4 or sweet-tasting solutions 5 to reduce potential for associated adverse effects of untreated pain.
Undoubtedly, Hartley and colleagues' work highlights the urgent need to identify optimum ways to reduce pain associated with retinopathy of prematurity examinations in highly vulnerable preterm neonates and supports existing knowledge regarding the need for close surveillance while receiving oral morphine. Further, it prompts investigation into the efficacy and dosing of morphine and other pharmacological and nonpharmacological treatments for procedure-related pain in this population.
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